Akademik Veri Yönetim Sistemi
Izmir Democracy University Health Sciences Journal, cilt.4, sa.1, ss.87-93, 2021 (Hakemli Dergi)
Cisplatin is a widely used antineoplastic agent, but it has side effects that decrease quality of life. Its neurotoxic effects lead to cognitive disorders during or after treatment in 70% of the patients. In this study, the efficiency of melatonin to reduce cisplatin-induced toxicity was investigated. Four subject groups were established using 24 adult male Wistar Albino rats. Neurotoxicity was produced by administering intraperitoneal (ip) cisplatin on the 1st, 5th, 9th and 13th day at a dose of 4 mg/kg. Intraperitoneal melatonin was applied to the treatment group for 13 days at a dose of 10 mg/kg/day and the groups were compared. Following sacrification on the 14th day, hippocampal tissues were excised. Cisplatin toxicity and melatonin efficiency were analyzed by calculating pyknosis and edema scores. It was observed that there was no significant difference between the Sham, Mel and Cisp+Mel groups in terms of pyknosis, but a marked increase in pyknotic neurons occurred in the group which was given cisplatin (p<0.01). It was found that edema in the hippocampal tissue increased markedly in the rats which were given cisplatin, but edema scores statistically significantly decreased when melatonin was given (p<0.01). Cisplatin and melatonin influence the same oxidative and apoptotic processes in opposite directions. In our study, we examined the effects of melatonin on cisplatin-induced toxicity and concluded that melatonin showed protective action against cisplatin-induced neurotoxic effects. Our conclusion indicated that cancer patients would be exposed to fewer neurotoxic side effects when cisplatin, a widely used chemotherapeutic drug, is used in combination with melatonin.